Literature DB >> 15511471

Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis.

Yasunori Matsuzaki1, Masao Edagawa, Tetsuya Shimizu, Masaki Hara, Masaki Tomita, Takanori Ayabe, Toshio Onitsuka.   

Abstract

BACKGROUND: Previously, we reported on the effectiveness of intrapleural hyperthermic perfusion with chemotherapy, a new treatment we developed for patients with malignant pleuritis. The present study analyzes the mechanism of the effectiveness of this therapy by examining the induction ratio of apoptosis among tumor cells following the perfusion treatment.
METHODS: This study included 11 consecutive patients with primary pulmonary adenocarcinoma and accompanying pleural seedlings and pleural effusions containing tumor cells but without distant metastasis. All patients underwent surgical resection of the primary lesion and then received sequential perfusion treatment. Tumor cells collected from the effusion both before and again at 24 hours following the perfusion treatment were subsequently examined using an immunocytochemical stain to determine apoptosis among tumor cells. The percentage of positively stained cells was expressed as the apoptotic index. We compared the survival rate of these 11 patients with the survival rate of a second group of 11 patients with malignant pleuritis who underwent surgical resection of the primary lesion but who did not receive the perfusion treatment (control group).
RESULTS: The ratio of spontaneous apoptosis of untreated tumor cells was 2.8% +/- 2.0%. Following the perfusion, apoptosis among tumor cells was 25.2% +/- 4.6%, clearly a significant increase. While the median survival time for patients receiving the perfusion treatment was 20 months, the median survival time for the control group was 6 months.
CONCLUSIONS: In patients with malignant pleuritis, intrapleural hyperthermic perfusion with chemotherapy induced potent apoptosis of tumor cells in the pleural cavity and also improved the survival rate of these patients as compared with patients who did not receive the perfusion treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15511471     DOI: 10.1016/j.athoracsur.2004.05.025

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

1.  Intrapleural perfusion thermo-chemotherapy for pleural effusion caused by lung carcinoma under VATS.

Authors:  Runlei Hu; Hong Jiang; Hu Li; Dongshan Wei; Guoqing Wang; Shenglin Ma
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Intrapleural hyperthermic perfusion using distilled water at 48 °C for malignant pleural effusion.

Authors:  Mingchen Ba; Hui Long; Yuandong Wang; Yunqiang Tang; Yinbing Wu; Xiangliang Zhang; Shuzhong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-26       Impact factor: 4.553

Review 3.  Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.

Authors:  Shuang Cai; Taryn R Bagby; M Laird Forrest
Journal:  Ther Deliv       Date:  2011-11

4.  Simple intrapleural hyperthermia at thoracoscopic exploration to treat malignant pleural effusion.

Authors:  Youngkyu Moon; Kyung Soo Kim; Jae Kil Park
Journal:  J Cardiothorac Surg       Date:  2015-10-28       Impact factor: 1.637

Review 5.  Current status of oncothermia therapy for lung cancer.

Authors:  Andras Szasz
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-04-10

Review 6.  Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis.

Authors:  Hua Zhou; Wei Wu; Xiaoping Tang; Jianying Zhou; Yihong Shen
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

7.  Magnetic carbon nanotubes for self-regulating temperature hyperthermia.

Authors:  Xudong Zuo; Chengwei Wu; Wei Zhang; Wei Gao
Journal:  RSC Adv       Date:  2018-03-27       Impact factor: 4.036

Review 8.  A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer.

Authors:  Kimberly Song; Raja M Flores
Journal:  Ann Transl Med       Date:  2021-06

9.  EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment.

Authors:  Hongjuan Zhang; Cheng Zhan; Ji Ke; Zhiqiang Xue; Aiqun Zhang; Kaifeng Xu; Zhirong Shen; Lei Yu; Liang Chen
Journal:  Oncotarget       Date:  2016-01-19

10.  Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis.

Authors:  Zi-Yi Zhao; Sha-Sha Zhao; Meng Ren; Zi-Ling Liu; Zhi Li; Lei Yang
Journal:  Oncotarget       Date:  2017-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.